On 22 June, IFPMA delivered a statement at the Human Rights Council (HRC) 53 Regular Session: Interactive dialogue on the right to health.
Read moreAcross the globe, people often associate tuberculosis (TB) with rows of beds in archaic sanitoriums. But this is not a disease of the past, it remains one of the world’s most deadly public health challenges and one our industry is determined to remedy. Following the COVID-19 pandemic, TB is once again the world’s leading cause...
Read more
The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Janis Bernat explains what we can learn from this experience.
Read more
On 7 June 2023, IFPMA hosted a unique opportunity to hear from 10 companies, about the different partnership models that supported the industry’s response to COVID-19. This open event included discussion on the challenges of scaling up manufacturing to meet global demand for vaccines and treatments, with representatives from MSD – Dr Reddy’s Laboratories; Gilead...
Read moreOn 6 June, IFPMA delivered a statement at the G20 “Strengthening Global Collaboration on Research and Development in MCMs (Diagnostics, Vaccines, and Therapeutics” side event on “Envisaging a Global R&D Network for Research in VTDs to enhance PPR” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read moreSince I joined the pharmaceutical industry over 35 years ago, we have seen incredible scientific progress in how we diagnose, prevent, and treat disease. A new generation of cancer treatments have transformed outcomes for patients. We’ve seen mRNA vaccines developed in response to the COVID pandemic, and personalized medicines have become a reality for patients...
Read more
On 4 June, IFPMA delivered a statement on Priority I “Health Emergencies Prevention, Preparedness, and Response” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read moreOn 4 June, IFPMA delivered a statement on Priority II “Strengthening cooperation in pharmaceutical sector with focus on availability and access to safe, effective, quality, and affordable medical countermeasures (MCM) – VTDs (vaccines, therapeutics, and diagnostics)” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read moreThe 76th World Health Assembly (WHA) was the first since the World Health Organization declared that COVID-19 was no longer a Public Health Emergency of International Concern. My WHA kicked off with IFPMA colleagues at the WHO Walk the Talk, which was a healthy start to a busy week ahead. The agenda saw a focus...
Read more
On 3 June, IFPMA delivered a statement at the PATH and CEPI side event on the “Global Vaccine Research Collaborative” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read moreOn 5 June, IFPMA delivered a statement on Priority III “Digital health innovations and solutions to aid Universal Health Coverage (UHC) and improve Healthcare Service Delivery” at the G20 3rd Health Working Group Meeting in Hyderabad.
Read moreThe ECOWAS Joint Assessment Procedure is a collaborative initiative among 15 National Regulatory Agencies in West Africa that ensures harmonized and streamlined market authorization of medical products across the region. This infographic provides an overview of key steps and timelines applicants need to bear in mind during the Joint Assessment Procedure.
Read more